Vyvanse (Lisdexamfetamine)
Vyvanse is a prodrug of d-amphetamine used primarily for treating ADHD & binge eating disorder, offering improved executive function & attention with a smoother onset & longer duration of action.
Evidence last reviewed: 05 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
The evidence supports Vyvanse's effectiveness in reducing ADHD symptoms and binge eating disorder symptoms, with a high safety and tolerability profile. However, more research is needed on its use in treatment-resistant depression, and individual responses may vary.
Binge eating disorder symptom reductionAdults with binge eating disorder · Systematic review and meta-analysisModerate
Lisdexamfetamine showed efficacy in reducing symptoms of binge eating disorder.
Efficacy in treatment-resistant depressionAdults with treatment-resistant depression · Systematic review and network meta-analysisModerate
Lisdexamfetamine was included among agents with significant response rates compared to placebo.
Cardiovascular safetyAdults with ADHD · Systematic review and network meta-analysisModerate
Lisdexamfetamine was assessed for cardiovascular effects, showing a safety profile consistent with other ADHD medications.
ADHD symptom reductionChildren, adolescents, and adults with ADHD · Systematic review and network meta-analysisHigh
Lisdexamfetamine was found to be effective in reducing ADHD symptoms compared to placebo.
Safety & tolerabilityAdults with ADHD · Systematic review and network meta-analysisHigh
Lisdexamfetamine was found to have a favorable safety & tolerability profile compared to other ADHD medications.